Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract] | |
Net revenues from research collaborators | 8.71M |
Operating expenses: | |
Research and development | 83.17M |
General and administrative | 17.99M |
Total operating expenses | 101.16M |
Loss from operations | -92.45M |
Other income (expense): | |
Equity in loss of joint venture (Regulus Therapeutics Inc.) | |
Interest income | |
Other (expense) income | 229K |
Total other income (expense) | 2.32M |
Loss before income taxes | |
Benefit from income taxes | |
Net loss | -90.13M |
Net loss per common share - basic and diluted | -1.05 |
Weighted average common shares used to compute basic and diluted net loss per common share | |
Comprehensive loss: | |
Net loss | -90.13M |
Foreign currency translation | |
Unrealized (loss) gain on marketable securities | -18.33M |
Comprehensive loss | -109.41M |
Non-cash stock-based compensation expenses included in operating expenses are as follows: | |
Research and development | |
General and administrative |